Zevra Therapeutics (ZVRA) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $0.07 and quarterly revenue of $31.72M.
In the most recent quarter (Q4), Zevra Therapeutics reported EPS of $0.19, beating estimates of $0.05 by 2.80%. Revenue came in at $34.13M, exceeding the estimate of $28.00M by 0.22%.
Zevra Therapeutics has beaten EPS estimates in 2 consecutive quarters.
Over the last 4 quarters, Zevra Therapeutics has averaged an EPS surprise of 1.07% and a revenue surprise of 0.15%.
Analyze the earnings history of Zevra Therapeutics using advanced sorting and filters.
The chart below shows Zevra Therapeutics's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Zevra Therapeutics's reported revenue compared to analyst estimates over recent quarters.
Zevra Therapeutics (ZVRA) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on March 9, 2026 for Q4.
The Actual EPS was $0.19, which beat the estimate of $0.05.
The Actual Revenue was $34.13M, which beat the estimate of $28.00M.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2026-03-09 | $0.19 | $0.05 | 280.0 % |
| Q3 | 2025-11-05 | $-0.01 | $-0.03 | 66.7 % |
| Q2 | 2025-08-12 | $1.24 | $1.40 | -11.4 % |
| Q1 | 2025-05-13 | $-0.06 | $-0.19 | 68.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2026-03-09 | $34.13M | $28.00M | 21.9 % |
| Q3 | 2025-11-05 | $26.06M | $26.60M | -2.01 % |
| Q2 | 2025-08-12 | $25.90M | $22.55M | 14.9 % |
| Q1 | 2025-05-13 | $20.40M | $16.96M | 20.3 % |